Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characteristics and mid-term follow-up of COVID-19 patients with hematological diseases: a retrospective study from a French tertiary care hospital.
Vallet N, Chevret S, Feghoul L, Aguinaga L, Bondeelle L, Kaphan E, Bertinchamp R, Soret J, Villesuzanne C, De Castro N, Sebert M, Boutboul D, Lengline E, Tudesq JJ, Rabian F, Adès L, Xhaard A, Di Blasi R, Raffoux E, Galicier L, Le Goff J, Delaugerre C, Bergeron A, Harel S; Saint-Louis CORE group. Vallet N, et al. Among authors: sebert m. Blood Cancer J. 2021 Jul 14;11(7):129. doi: 10.1038/s41408-021-00512-5. Blood Cancer J. 2021. PMID: 34262018 Free PMC article. No abstract available.
Equivalent outcomes using reduced intensity or conventional myeloablative conditioning transplantation for patients aged 35 years and over with AML.
Sébert M, Porcher R, Robin M, Adès L, Boissel N, Raffoux E, Xhaard A, Dhedin N, Larghero J, Himberlin C, Delmer A, Fenaux P, Dombret H, Socié G, de Latour RP. Sébert M, et al. Bone Marrow Transplant. 2015 Jan;50(1):74-81. doi: 10.1038/bmt.2014.199. Epub 2014 Sep 22. Bone Marrow Transplant. 2015. PMID: 25243624 Clinical Trial.
Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast-phase myeloproliferative neoplasms.
Devillier R, Raffoux E, Rey J, Lengline E, Ronchetti AM, Sebert M, Boissel N, Robin M, Vey N, Kiladjian JJ, Dombret H, Cluzeau T. Devillier R, et al. Among authors: sebert m. Br J Haematol. 2016 Feb;172(4):628-30. doi: 10.1111/bjh.13516. Epub 2015 Jun 10. Br J Haematol. 2016. PMID: 26061174 Free article. No abstract available.
Are myelodysplastic syndromes and acute myeloid leukaemia occurring during the course of lymphoma always therapy related?
Bigenwald C, Harel S, Chevignon F, Roos-Weil D, Bernard OA, Amorim S, Brice P, Adès L, Nloga AM, Sébert M, Braun T, Eclache V, Thieblemont C, Fenaux P. Bigenwald C, et al. Among authors: sebert m. Br J Haematol. 2018 Jan;180(2):304-308. doi: 10.1111/bjh.14323. Epub 2016 Sep 23. Br J Haematol. 2018. PMID: 27662562 Free article. No abstract available.
Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies.
Ades L, Prebet T, Stamatoullas A, Recher C, Guieze R, Raffoux E, Bouabdallah K, Hunault M, Wattel E, Stalnikiewicz L, Toma A, Dombret H, Vey N, Sebert M, Gardin C, Chaffaut C, Chevret S, Fenaux P. Ades L, et al. Among authors: sebert m. Haematologica. 2017 Apr;102(4):728-735. doi: 10.3324/haematol.2016.151894. Epub 2016 Dec 29. Haematologica. 2017. PMID: 28034993 Free PMC article.
A landscape of germ line mutations in a cohort of inherited bone marrow failure patients.
Bluteau O, Sebert M, Leblanc T, Peffault de Latour R, Quentin S, Lainey E, Hernandez L, Dalle JH, Sicre de Fontbrune F, Lengline E, Itzykson R, Clappier E, Boissel N, Vasquez N, Da Costa M, Masliah-Planchon J, Cuccuini W, Raimbault A, De Jaegere L, Adès L, Fenaux P, Maury S, Schmitt C, Muller M, Domenech C, Blin N, Bruno B, Pellier I, Hunault M, Blanche S, Petit A, Leverger G, Michel G, Bertrand Y, Baruchel A, Socié G, Soulier J. Bluteau O, et al. Among authors: sebert m. Blood. 2018 Feb 15;131(7):717-732. doi: 10.1182/blood-2017-09-806489. Epub 2017 Nov 16. Blood. 2018. PMID: 29146883 Free article.
A phase II study of the efficacy and safety of an intensified schedule of azacytidine in intermediate-2 and high-risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des Myelodysplasies (GFM).
Ades L, Guerci-Bresler A, Cony-Makhoul P, Legros L, Sebert M, Braun T, Delaunay J, Desseaux K, Chevret S, Fenaux P. Ades L, et al. Among authors: sebert m. Haematologica. 2019 Apr;104(4):e131-e133. doi: 10.3324/haematol.2018.203885. Epub 2018 Oct 31. Haematologica. 2019. PMID: 30381302 Free PMC article. Clinical Trial. No abstract available.
Non-allogeneic immunotherapy in acute myeloid leukaemia.
Adès L, Sébert M, Fenaux P. Adès L, et al. Among authors: sebert m. Lancet Haematol. 2019 Sep;6(9):e443-e444. doi: 10.1016/S2352-3026(19)30159-0. Epub 2019 Aug 7. Lancet Haematol. 2019. PMID: 31400960 No abstract available.
Germline DDX41 mutations define a significant entity within adult MDS/AML patients.
Sébert M, Passet M, Raimbault A, Rahmé R, Raffoux E, Sicre de Fontbrune F, Cerrano M, Quentin S, Vasquez N, Da Costa M, Boissel N, Dombret H, Peffault de Latour R, Socié G, Itzykson R, Fenaux P, Soulier J, Adès L, Clappier E. Sébert M, et al. Blood. 2019 Oct 24;134(17):1441-1444. doi: 10.1182/blood.2019000909. Blood. 2019. PMID: 31484648 Free article.
106 results